AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE

Semaglutide in obesity

  • Nahid Rao Department of Pharmacy Practice, Division of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India.
  • Reenoo Jauhari Assistant Professor, Department of Pharmacy Practice, Division of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India.
  • Vaishali Sati Department of Pharmacy Practice, Division of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India.
  • Pallavi Godiyal Department of Pharmacy Practice, Division of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India.
DOI https://doi.org/10.31069/japsr.v5i2.02

Abstract

Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.

Keywords: Bimagrumab, Clinical trials, Diabetes mellitus, GLP-1 analogues, Obesity, Pioneer trials, Select trials, Semaglutide, Setmelanotide, Step trials, Sustain trials, Tirzepatide

Downloads

Download data is not yet available.
Statistics
894 Views | 838 Downloads
How to Cite
Rao, N., R. Jauhari, V. Sati, and P. Godiyal. “AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE”. Journal of Applied Pharmaceutical Sciences and Research, Vol. 5, no. 2, Sept. 2022, pp. 3-16, doi:10.31069/japsr.v5i2.02.
Issue
Vol 5 No 2 (2022): Volume 5, Issue 2, 2022
Section
Review Articles

Most read articles by the same author(s)